Association between GvHD and nivolumab in the FDA adverse event reporting system

被引：7
|
作者：
Oshima, Y. [1 ]
Tanimoto, T. [2 ]
Yuji, K. [1 ]
Tojo, A. [1 ]
机构：
[1] Univ Tokyo, Inst Med Sci, Tokyo, Japan
[2] Tokiwa Fdn, Jyoban Hosp, Fukushima, Japan
来源：
BONE MARROW TRANSPLANTATION | 2017年 / 52卷 / 10期
关键词：
HOST-DISEASE LETHALITY; LYMPHOMA; BLOCKADE; TRANSPLANTATION; EFFICACY;
D O I：
10.1038/bmt.2017.158
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：1463 / 1464
页数：2
相关论文
共 50 条
  • [1] Association between GvHD and nivolumab in the FDA adverse event reporting system
    Y Oshima
    T Tanimoto
    K Yuji
    A Tojo
    [J]. Bone Marrow Transplantation, 2017, 52 : 1463 - 1464
  • [2] The Association Between Use of Rivastigmine and Pneumonia: Systematic Analysis of FDA Adverse Event Reporting System
    Morris, Robert
    Umeukeje, Gibret
    Bu, Kun
    Cheng, Feng
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2021, 83 (03) : 1061 - 1071
  • [3] A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data
    Bin Wu
    Qiaozhi Hu
    Fangyuan Tian
    Fengbo Wu
    Yuwen Li
    Ting Xu
    [J]. Scientific Reports, 11
  • [4] A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data
    Wu, Bin
    Hu, Qiaozhi
    Tian, Fangyuan
    Wu, Fengbo
    Li, Yuwen
    Xu, Ting
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [5] An evaluation of the FDA adverse event reporting system and the potential for reporting bias
    Monnot, Andrew D.
    Fung, Ernest S.
    Compoginis, Goli S.
    Towle, Kevin M.
    [J]. JOURNAL OF COSMETIC DERMATOLOGY, 2021, 20 (06) : 1849 - 1854
  • [6] Association Between Colitis and Immune Checkpoint Inhibitor Use: Analysis of the FDA Adverse Event Reporting System (FAERS)
    Tunio, Nahel A.
    Cooper, Gregory S.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S76 - S77
  • [7] Association Between Paraesthesia and Local Anesthetics: Data Mining of the Public Version of the FDA Adverse Event Reporting System
    Piccinni, C.
    Gissi, D. B.
    Koci, A.
    Servidio, D.
    Cervellati, F.
    Poluzzi, E.
    [J]. DRUG SAFETY, 2013, 36 (09) : 907 - 908
  • [8] The association between GLP-1 receptor agonist and diabetic ketoacidosis in the FDA adverse event reporting system
    Yang, Zheng
    Yu, Meng
    Mei, Mei
    Chen, Chongxin
    Lv, Yuhuan
    Xiang, Linyu
    Li, Rong
    [J]. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2022, 32 (02) : 504 - 510
  • [9] Vedolizumab Adverse Events: Analysis of the FDA Adverse Event Reporting System
    Jow, Steven
    Hutfless, Susan
    [J]. INFLAMMATORY BOWEL DISEASES, 2017, 23 : S35 - S36
  • [10] Identification of Generic Drugs in the FDA Adverse Event Reporting System
    Iyer, Geetha S.
    Marimuthu, Sathiya Priya
    Segal, Jodi B.
    Singh, Sonal
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 406 - 407
12345